Argenx (ARGX)
(Delayed Data from NSDQ)
$375.81 USD
-10.99 (-2.84%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $376.24 +0.43 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
argenex SE [ARGX]
Reports for Purchase
Showing records 141 - 160 ( 280 total )
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Key Takeaways From argenx R&D Day as Company Lays Out Vision for Next Few Years; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
2021 R&D Day Highlights; The Journey Adds New Indications
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
argenx to Unveil 5th & 6th Efgartigimod Indications and Phase 1 Data for -117 at Virtual R&D Day; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
J&J Returns Cusatuzumab Though argenx?s Focus Remains on Efgartigimod and Immunology Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Parting Is Sweeter After $500+M; Janssen Returns Cusa
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Building-Out the Global Efgartigimod Franchise With J-MMA Filing Acceptance; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Safety Rules: We Upgrade argenx as Survey Points to Market Leadership for Efgartigimod
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
We See Efgartigimod Emerging as the Leader in the FcRn Market; Upgrade to Buy, PT to $400
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Key Takeaways From Our Coverage at the American Academy of Neurology 2021 Virtual Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Additional Nipocalimab Data Doesn?t Offer Clarity on Albumin Levels or Potential Cholesterol Changes
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
With MG BLA Submitted, Focus Shifts to Launch Preparations; Reiterate Neutral Price Target up to $320
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Not Too Early to Think of Christmas; Efgart PDUFA Set in Dec.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D